ArticleDiscover oncology2026
The research landscape and future of targeting super-enhancers for cancer therapy: a bibliometric analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSuper-enhancers are specialized transcriptional regulatory elements pivotal for establishing and maintaining cell identity. Since their identification in 2013, SEs have garnered considerable attention as promising therapeutic targets in oncology. However, despite substantial progress, the molecular mechanisms and translational potential of SE-targeted strategies are not fully systematized, necessitating a comprehensive bibliometric analysis to map the intellectual landscape and guide future research.
methodsWe conducted a bibliometric analysis of 928 publications (2013-2024) from the Web of Science Core Collection using VOSviewer, CiteSpace, and R. The study employed co-occurrence, co-citation and cluster analysis to profile the research landscape, identifying leading contributors, influential works, and conceptual themes. Temporal analysis and burst detection were further applied to track evolution and pinpoint emerging frontiers in super enhancer-targeted cancer therapy.
resultsThe intellectual architecture is dominated by the United States and China, with Harvard Medical School and Shanghai Jiao Tong University as pivotal institutions and Young Richard A. as the most influential author. Temporal mapping revealed a progression from core themes like "gene expression" and "selective inhibition" to contemporary foci on "drug resistance" and the nascent frontier of "enhancer RNA", signaling a collective shift from basic biology to therapeutic innovation.
conclusionThis study consolidates a decade of progress in super enhancer-targeted cancer therapy, mapping its evolution from mechanistic discovery to translational ambition. By pinpointing emergent frontiers such as enhancer RNA, our analysis provides a strategic roadmap to guide future research and accelerate the clinical translation of super enhancer-directed strategies, ultimately aiming to overcome persistent therapeutic barriers such as drug resistance in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.